{"id":"pathogen-reduced-cryoprecipitate","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombosis"},{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Transfusion-related acute lung injury (TRALI)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cryoprecipitate is the cold-insoluble fraction of plasma containing high concentrations of fibrinogen and von Willebrand factor. The pathogen-reduction process uses solvent-detergent or photochemical treatment to inactivate viruses, bacteria, and other pathogens while maintaining the functional clotting proteins. This product is used to restore fibrinogen and other hemostatic factors in patients with deficiencies or consumption coagulopathy.","oneSentence":"Pathogen-reduced cryoprecipitate is a blood product containing fibrinogen, von Willebrand factor, fibronectin, and other clotting factors that have been treated to inactivate pathogens while preserving hemostatic function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:00:00.517Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Fibrinogen replacement in patients with congenital or acquired fibrinogen deficiency"},{"name":"Massive transfusion and disseminated intravascular coagulation (DIC)"},{"name":"Perioperative bleeding management"}]},"trialDetails":[{"nctId":"NCT07265843","phase":"PHASE4","title":"Fibrinogen in Liver Transplant","status":"NOT_YET_RECRUITING","sponsor":"Trauma Hemostatis and Oxygenation Research (THOR) Network","startDate":"2026-01-01","conditions":"Liver Transplant Surgery","enrollment":60},{"nctId":"NCT05711524","phase":"PHASE4","title":"Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2023-04-01","conditions":"Hypofibrinogenemia, Bleeding","enrollment":208},{"nctId":"NCT07218185","phase":"","title":"Comparative Effectiveness of INTERCEPT Fibrinogen Complex (IFC) and Cryoprecipitate-AHF (Cryo-AHF) for Treatment of Trauma Associated Hemorrhage","status":"NOT_YET_RECRUITING","sponsor":"Cerus Corporation","startDate":"2026-05","conditions":"Hypofibrinogenemia, Hemorrhage","enrollment":320},{"nctId":"NCT06764927","phase":"PHASE4","title":"Fibrinogen in Liver Transplant Subjects","status":"NOT_YET_RECRUITING","sponsor":"Ezeldeen Abuelkasem","startDate":"2025-10-31","conditions":"Liver Transplant Surgery","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Pathogen-Reduced Cryoprecipitate","genericName":"Pathogen-Reduced Cryoprecipitate","companyName":"Weill Medical College of Cornell University","companyId":"weill-medical-college-of-cornell-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"Pathogen-Reduced Cryoprecipitate is used to treat conditions such as hypofibrinogenemia, bleeding, and hemorrhage, particularly in patients undergoing liver transplant surgery. It is a type of cryoprecipitate that has been pathogen-reduced, although the exact mechanism of action is not specified as a small molecule modality.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}